

22 July 2025

Treatment of Melanoma

Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

<input type="checkbox"/>	Cobimetinib	<5*
<input type="checkbox"/>	Dabrafenib	<5*
<input type="checkbox"/>	Dabrafenib + Trametinib	20
<input type="checkbox"/>	Dacarbazine	<5*
<input type="checkbox"/>	Denosumab	<5 (+6 in conjunction with other regimens)
<input type="checkbox"/>	Encorafenib + Binimetinib	30
<input type="checkbox"/>	Ipilimumab monotherapy	<5*
<input type="checkbox"/>	Ipilimumab + Nivolumab	10
<input type="checkbox"/>	Nivolumab monotherapy	10
<input type="checkbox"/>	Nivolumab + Relatlimab	<5*
<input type="checkbox"/>	Pembrolizumab	45
<input type="checkbox"/>	Trametinib	<5*
<input type="checkbox"/>	Vemurafenib	<5*
<input type="checkbox"/>	Vemurafenib + Cobimetinib	<5*
<input type="checkbox"/>	Other active systemic anti-cancer therapy	
	Tebentafusb	<5*
<input type="checkbox"/>	Palliative care only	
	This information is not available	

Q2. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?

<input type="checkbox"/>	Ipilimumab (monotherapy)	<5*
<input type="checkbox"/>	Nivolumab (monotherapy)	<5*
<input type="checkbox"/>	Nivolumab AND Ipilimumab (combination)	11
<input type="checkbox"/>	Nivolumab AND Relatlimab	<5*
<input type="checkbox"/>	Pembrolizumab	9
<input type="checkbox"/>	Any Targeted Therapy	
	Dabrafenib	<5*
	Dabrafenib AND Trametinib	<5*
	Encorafenib AND Binimetinib	6
	Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)	9
<input type="checkbox"/>	Other active systemic anti-cancer therapy	
	Tebentafusp	<5*

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

22 July 2025

Q3. Does your trust participate in any clinical trials for Melanoma? If so, please provide the name of each trial, and the number of patients taking part.

Currently one melanoma trial – PREMIUM (PeRioperative Encorafenib+binimetinib in BRAFV600 MUtant clinically detected AJCC stage III (B/C/D) or oligometastatic stage IV Melanoma) – <5* patients has been recruited.

*Where numbers are low we have indicated <5 rather than give the exact figure. We feel that providing the exact figure has the potential to make people identifiable and so that information is exempt from release under Section 40(2) of the Freedom of Information Act 2000.